D-1100-2020 Class II Ongoing

Recalled by Teva Pharmaceuticals USA — Parsippany, NJ

FDA drug recall D-1100-2020 was initiated by Teva Pharmaceuticals USA on Mar 25, 2020 and is designated Class II. Reason for recall: CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products. The recall status is ongoing.

Recall details

Product Type
Drugs
Report Date
Apr 15, 2020
Initiation Date
Mar 25, 2020
Voluntary/Mandated
Voluntary: Firm initiated

Product description

LOSARTAN POTASSIUM TABLETS, USP 25 mg, Bulk, Rx only, For Further Manufacturing, Packing or Repackaging only, Manufactured by: Arrow Pharma (Malta) Ltd., Birzebbugia Malta NDC 0591-3745-00

Reason for recall

CGMP Deviations: impurity for N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) detected in the active pharmaceutical ingredient (API) used to manufacture finished products.

Distribution pattern

Bulk product was distributed to one re-packager in California.

Code information

Lots 1207344A, exp. date 06/2020; 1207343A, 1207342A, exp. date 07/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1100-2020
openFDA file date
Nov 16, 2026
Loaded by RegDataLab
Nov 17, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1100-2020. Report a data issue: hello@regdatalab.com.